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Increased extracellular matrix material is a pathological
hallmark of diabetic nephropathy. In addition to collagens, a
variety of non-collagenous glycoproteins such as fibronectin
also accumulate in the kidney of diabetics. The effect of
diabetes on degradative pathways, in particular those
involving non-collagenous proteins, are relatively
unexplored. In this study, we determined the expression of
the major matrix metalloproteinase (MMP) responsible for
degrading the non-collagenous matrix glycoprotein
fibronectin. Furthermore, the modulation of these MMPs by
advanced glycation end products (AGE), a key factor in the
diabetic milieu, was explored. Exposure of mesangial cells to
AGEs led to a significant reduction in MMP-7, but not MMP-3
or -10. MMP-7 expression was normalized by both
aminoguanidine, an inhibitor of glycation product formation,
or by a neutralizing anti-transforming growth factor-b
(TGF-b) antibody. In streptozotocin-induced diabetic rats, the
diminution in MMP-7 expression and excessive fibronectin
accumulation were attenuated by aminoguanidine. Humans
with type 2 diabetes and nephropathy displayed similar
alterations in MMP-7 to their rodent counterparts. Our
findings suggest that diminished expression of the
glycoprotein-degrading enzyme, MMP-7, may play a role in
fibronectin accumulation in the diabetic kidney in response
to AGEs and/or TGF-b.
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Increased extracellular matrix (ECM) is a characteristic
feature of diabetic nephropathy that is directly linked to
declining renal function.1 However, rather than being a static
phenomenon, ECM is in dynamic flux with both synthetic
and degradative components contributing to its turnover. In
diabetes, experimental studies using cell culture and in vivo
approaches have both identified reduced gene expression and
activity of the major collagen degradative enzymes: matrix
metalloproteinase-2 (MMP-2) and MMP-9 in the diabetic
kidney.2,3 In addition to the collagens, non-collagenous
glycoproteins are also a major component of the renal ECM
that are degraded by other MMPs.4 However, the effect of
diabetes on the degradative pathways of non-collagenous
proteins in the kidney, such as MMP-3, -7, and -10,5 is
relatively unexplored.
A number of molecular pathways that include the
formation of advanced glycation end products (AGEs) have
been implicated in the pathogenesis of diabetic nephropathy.6
Inhibitors of AGE formation have been shown to reduce the
structural and functional manifestations of kidney disease in
diabetic rodents,7,8 including alterations in collagen gene
expression and deposition.9 While inhibiting AGE formation
has been shown to modulate the expression of the collagen-
degrading enzyme, MMP-2,3 its effects on MMPs responsible
for degrading non-collagenous proteins has not been
determined.
Transforming growth factor-b (TGF-b) is a pro-sclerotic
growth factor that has been consistently implicated in the
pathogenesis of diabetic nephropathy,10 mediating matrix
accumulation by both increasing its synthesis and reducing
its degradation.11 Indeed, in addition to its effects on
collagen-degrading enzymes,12 TGF-b has also been shown
to suppress the expression of several MMPs through a TGF-b
inhibitory element in their promoter regions.13,14
In light of the relationship between AGEs, TGF-b, and
MMPs in diabetic nephropathy, the aims of this study were
several fold. We firstly sought to determine the effect of AGEs
on MMP expression in cultured mesangial cells. As our
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results showed that the expression of one of the MMPs,
MMP-7 was significantly altered, we investigated the relation-
ship between MMP-7 and TGF-b. We then explored the
effects of diabetes and the inhibitor of AGE formation,
aminoguanidine, on MMP-7 mRNA and protein in the
kidneys of diabetic rats. Finally, to determine whether the
findings in cell culture and rodents were applicable to
humans, we sought to determine whether the expression of
MMP-7 was also altered in human diabetic nephropathy.
RESULTS
The effect of AGEs on MMP expression by mesangial cells
Assessed by real-time reverse transcriptase-polymerase chain
reaction (RT-PCR), GlyAlb, and Ne-carboxymethyl lysine-
bovine serum albumin (CML-BSA) had no effect on the
expression of the stromelysins MMP-3 and -10 (Figure 1). By
contrast, the addition of AGEs, either as glycated albumin
(GlyAlb) or CML-BSA, induced a substantial diminution in
the gene and protein expression of the matrilysin MMP-7,
when compared with cells incubated in non-glycated control
albumin (Figure 1). This reduction in MMP-7 mRNA was not
observed when cells were incubated in albumin, in which
glycation had been inhibited by co-incubation with amino-
guanidine.
The effect of AGEs on MMP-7 activity in mesangial cell-
conditioned media
Using a fluorescently labeled substrate to determine the effect
of AGEs on MMP-7 activity in media obtained from
mesangial cells, the addition of either GlyAlb or CML-BSA
was found to decrease MMP-7 activity by 2- and 3–fold,
respectively, compared with cells incubated in control
albumin. This decrease was not observed when cells were
cultured in the presence of albumin in which glycation had
been prevented by the addition of aminoguanidine (Figure 2).
The effect of TGF-b on expression and activity of MMP-7 in
mesangial cells
As with GlyAlb and CML-BSA, recombinant TGF-b also
induced a significant reduction in MMP-7 gene and protein
expression in mesangial cells cultured in 5 mM glucose
(Figure 3a and b). In concordance with the gene and protein
data, the activity of MMP-7 was also decreased in a dose-
dependent manner by TGF-b (2 ng: 78.676.9 and 10 ng:
24.778.2) when compared with control values (12077.8
relative fluorescence units (RFU)). Moreover, the addition of
TGF-b neutralizing antibody to mesangial cells prevented the
reduction in MMP-7 mRNA and activity induced by GlyAlb
(Figure 3c and d).
Rodent studies
Animal characteristics. Rodents characteristics are shown
in Table 1. All animals that received streptozocin became
diabetic (blood glucose X15 mmol/l). Treatment of the
diabetic animals with aminoguanidine had no effect on blood
glucose levels, HbA1c, or body weight.
The effect of diabetes on MMPs in kidney tissue
When compared with control animals, MMP-7 mRNA
(Figure 4a and b) and activity (Figure 4c) were substantially
reduced in the kidneys of untreated diabetic rats. In contrast,
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Figure 1 | The effect of GlyAlb and CML-BSA on the expression of MMP-7 by mesangial cells. Cells were cultured in the presence of either
control, GlyAlb, GlyAlbþAG, or CML-BSA before measurement of (a) MMP-3, -7, and -10 gene expression by quantitative real-time RT-PCR
results expressed as a percentage of control values or (b) MMP-3, -7, and -10 protein concentration by ELISA control (open bar), GlyAlb (filled
bar), GlyAlbþAG (striped bar), and CML-BSA (striped bar). *Po0.05 significantly different from control, Po0.05 versus GlyAlb.
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diabetic rats treated with aminoguanidine showed levels of
MMP-7 gene expression and activity that approached those
of non-diabetic animals. No effect of aminoguanidine on
MMP-7 activity was observed in non-diabetic rats.
Fibronectin immunohistochemistry
At 32 weeks, diabetic rats showed significant accumulation of
fibronectin in both glomeruli and tubulointerstitial compart-
ments, when compared with non-diabetic controls (Figure
5a–d). Blockade of AGE formation with aminoguanidine was
associated with a reduction in immunostainable fibronectin
in the kidneys of diabetic rats.
Gene expression of MMP-7 and fibronectin in human kidney
biopsies
As in the rodent studies, MMP-7 gene expression was also
reduced in human kidney biopsies from patients with
diabetic nephropathy compared with controls. Similarly,
fibronectin immunostaining was also increased in the kidneys
of diabetic humans compared with nephrectomy controls
(Figure 6a and b).
DISCUSSION
The pathological hallmark of progressive renal disease is the
accumulation of ECM in the glomerulus15 and tubulointer-
stitium16 with changes at both sites correlating closely with
declining renal function. This accumulation, results from an
imbalance between synthetic and degradative pathways, and
while the mechanisms mediating increased synthesis have
been the focus of considerable attention, changes in the
matrix degradative pathway in progressive kidney disease
have been less extensively explored. Two enzyme systems are
largely responsible for matrix degradation: the plasmin-
plasminogen activator system and the MMPs, a family of at
least 26 zinc-dependent proteases that are active at neutral
pH.17 Previous studies using mesangial cells have shown
reduced ECM degradation in a high glucose environment
with evidence of decreased activities of the major collagen-
degrading enzymes in both the in vitro and in vivo
settings.18–20 The present report extends these observations
by demonstrating that MMP-7, but not other metalloprotei-
nases responsible for the degradation of non-collagenous
glycoproteins such as MMP-3 and -10, is reduced in the
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Figure 2 | The effect of GlyAlb and CML-BSA on MMP-7 activity in
conditioned media collected from mesangial cells. Cells were
cultured in the presence of either control, GlyAlb, GlyAlbþAG, or
CML-BSA before measurement of MMP-7 activity by fluorescence
results expressed as relative fluorescence units (RFU). Control (open
bar), GlyAlb (filled bar), GlyAlbþAG (striped bar), and CML-BSA
(striped bar). *Po0.05 significantly different from control, Po0.05
versus GlyAlb.
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Figure 3 | The role of TGF-b in regulation of expression of MMP-7. The effect of addition of rhTGF-b on (a) gene expression of MMP-7
measured by quantitative RT-PCR and (b) protein concentration in conditioned media by ELISA. The effect of addition of anti-TGF-b antibody
on the (c) gene expression of MMP-7 measured by RT-PCR (insert) and quantitative RT-PCR, and (d) MMP-7 activity determined in culture media
of mesangial cells cultured in the presence of either control (hollow bars) or GlyAlb (hatched bars). *Po0.05 significantly different from control,
Po0.05 significantly different from TGF-b.
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diabetic kidney and that AGEs, acting via TGF-b-dependent
mechanisms contribute to this process.
Chronic hyperglycemia, a necessary prerequisite for the
development of diabetic nephropathy leads to the formation
of long-lived non-enzymatically glycated proteins referred to
as AGEs. As a consequence of increased substrate (glucose)
availability, AGEs accumulate at an accelerated rate in
patients with diabetes, where they have been postulated to
play a major role in the pathogenesis of the microvascular
complications of diabetes.21 Aminoguanidine is a powerful
blocker of the AGE pathway, though it has been largely
supplanted in the clinical arena by other AGE formation
inhibitors, cross-link breakers, and receptor antagonists.22
Nevertheless, this compound remains a useful tool with
which to assess the biological relevance of AGEs in both the
in vitro and in vivo contexts. In this study, we found that
aminoguanidine attenuated the reduced expression and
activity of MMP-7 in mesangial cells exposed to AGEs.
Similarly, MMP-7 mRNA was also diminished in the kidneys
of streptozocin-induced diabetic rats, a rodent model where
increased AGE deposition has been shown previously.23
Moreover, as in cell culture, aminoguanidine treatment in
diabetic rats resulted in MMP-7 expression and activity
similar to that found in the kidneys of control, non-diabetic
rats.
MMP-7, unlike most other family members of this group
of enzymes is constitutively expressed by most adult tissues.24
It has broad substrate specificity which includes not only
ECM glycoproteins such as fibronectin, but also collagens
and a range of non-matrix proteins.25 Increased MMP-7
expression has been reported in adult polycystic kidney
disease,26 an hereditary disorder characterized by expanding
cysts with atrophy of surrounding normal structures and
Table 1 | Clinical data: animal studies
Body weight (g) SBP (mm Hg) HbA1c UAE (mg/day)
Control 617715 12374 2.570.33 1.2570.39
Diabetic 487725* 13675 14.971.12w 7.5270.93w
Diabetic+AG 452729* 12974 13.771.25w 4.8970.80*,z
AG, aminoguanidine; SBP, systolic blood pressure; UAE, urinary albumin excretion.
*Po0.05 and wPo0.01 versus non-diabetic control rats, zPo0.05 versus untreated diabetic rats.
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Figure 4 | Analyses of rat kidney tissues. Gene expression of MMP-7
in tissue obtained from non-diabetic control, AG-treated control,
diabetic, and AG-treated diabetic rat glomeruli, (a) representative
RT-PCR gel, (b) quantitative real-time RT-PCR results, and (c) MMP-7
activity in tissue obtained from non-diabetic control, AG-treated
control, diabetic, and AG-treated diabetic rat glomeruli. Results
expressed as relative fluorescence units (RFU). *Po0.05 significantly
different from control, Po0.05 versus untreated diabetic.
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Figure 5 | Fibronectin deposition in the kidney of control,
diabetic, and diabetic rats treated with aminoguanidine.
Representative photomicrograph showing fibronectin
immunostaining in the kidney of (a) control, (b) diabetic, and diabetic
rats treated with (c) AG and (d) analysis of fibronectin deposition in
rat kidney tissues, as a proportion of immunostainable fibronectin in
control, diabetic, and diabetic rats treated with AG. *Po0.05
significantly different from control, Po0.05 versus untreated diabetic.
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dissolution of the intervening matrix. In contrast, the
diabetic kidney is characterized by ECM accumulation and
reduced MMP activity with previous studies having shown
reductions in the collagen-degrading enzymes, MMP-2 and -
9.2,20 Similarly, previous studies in cultured mesangial cells
have also shown that high glucose reduces the expression of
MMP-7,27 and in this study, we show that AGEs contribute to
this process by a mechanism possibly involving induction of
TGF-b.
In addition to the collagens, a range of non-collagenous
glycoproteins also accumulate in diabetic nephropathy.28
Among these, fibronectin has been identified as a major
glycoprotein in both the glomerulus and tubulointerstitium
in experimental and human diabetic kidney disease.28,29
Although increased production of fibronectin in the diabetic
kidney has been identified previously,30,31 this study indicates
that reduced degradation is also a likely contributor to its
accumulation in the diabetic kidney.
Numerous in vitro31,32 rodent33,34 and human studies31,35
have reported increased TGF-b in diabetes. The ability of
TGF-b to induce ECM formation has been the predominant
focus of most studies in diabetic nephropathy, however this
prosclerotic growth factor is also a potent inhibitor of MMP
gene transcription.11 This widely expressed growth factor is
induced by a range of factors present in the diabetic milieu,
including not only high glucose32 but also AGEs.36 Like
AGEs, TGF-b was also noted in this study to induce a
reduction in MMP-7 expression, and that the effects of AGEs
could be attenuated with TGF-b neutralization. These
findings suggest that induction of TGF-b expression by
AGEs may contribute to the diminution in MMP-7
expression and thereby ECM accumulation in diabetes.
Cell culture and rodents experiments provide a convenient
platform for advancing our understanding of pathophysio-
logical processes. However, the major differences between
mammalian species are important limitations in extrapolat-
ing the findings to human illness. Although we did not have
biopsy material from patients treated with a glycation or
TGF-b inhibitor, we were able confirm low MMP-7 mRNA
and fibronectin accumulation in human diabetic kidney
biopsies, suggesting that the changes we observed in rodents
are also applicable to human disease. Whether the demon-
strated findings are specific to human diabetic nephropathy
or more a feature of progressive, proteinuric renal disease,
remains to be determined.
In summary, the present report indicates that diminished
expression of the glycoprotein-degrading enzyme, MMP-7, in
response to AGEs and/or TGF-b may play a role in the
accumulation of matrix proteins such as fibronectin in the
diabetic kidney.
MATERIALS AND METHODS
Preparation of GlyAlb
To prepare GlyAlb, endotoxin-free bovine serum albumin (BSA:
100 mg/ml; Sigma, St Louis, MO, USA) was dissolved in phosphate-
buffered saline (PBS) and incubated at 371C in the presence of
500 mM D-ribose for 10 days, as described previously.37 The resulting
solution containing GlyAlb was dialyzed against five changes of 5 l of
H2O to remove excess ribose before being aliquoted and stored at
201C. Albumin incubated either in the absence of ribose (control)
or in which glycation was inhibited by co-incubation in the presence
of equimolar concentrations of ribose and aminoguanidine
(GlyAlbþAG; Sigma), an inhibitor of AGE formation,37 were used
as control. The degree of glycation in each solution was assessed by
measurement of fluorescence at an excitation wavelength of 370 nm
and emission of 440 nm (Hitachi, Spectrofluorimeter Model:L3000,
North Ryde, Australia and enzyme-linked immunosorbent assay
(ELISA) (Cyclex Co., Nagana, Japan). The fluorescence content in
relative fluorescence units was 48.2712.5 for control Alb,
198.3726.3 for GlyAlb, and 82.7710.2 for GlyAlbþAG. As
described previously,38 the molecular size of the GlyAlb was greater
than control when analyzed by sodium dodecyl sulfate polyacryla-
mide gel electrophoresis analysis under reducing conditions,
followed by Coomassie staining. In contrast, the control BSA and
aminoguanidine BSA preparations did not have these high-
molecular-mass forms (data not shown). By competitive ELISA,
using synthetic CML as the standard, the CML content of the
preparations was 9.271.4 (pmol CML/mg BSA) for GlyAlb and was
undetectable (o1) for control and GlyAlbþAG.
In addition, we also generated the well-characterized AGE, CML-
BSA, as reported previously.38 In brief, 176 mg BSA was dissolved in
sodium phosphate buffer to which 14.3 mg (0.155 M) glyoxylic acid
(Sigma) was added, together with 19.8 mg (0.315 M) of the reducing
agent, sodium cyanoborohydride (Sigma), and incubated for 24 h at
371C. All preparations were extensively dialyzed in PBS, reducing
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Figure 6 | Analyses of human kidney tissues. (a) Gene expression
of MMP-7 by quantitative real-time RT-PCR in kidney tissue obtained
from non-diabetic and diabetic humans. (b) Representative
photomicrograph of immunohistochemical staining for fibronectin in
non-diabetic and diabetic human kidney biopsy samples. *Po0.05
significantly different from non-diabetic.
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agent, and unincorporated sugars. The CML concentration in the
solution was determined by competitive ELISA as described and was
found to be 1371.4 pmol CML/mg BSA.
Cell-culture studies
Human mesangial cells were isolated from fetal kidneys using a
sieving technique as described previously.2 The mesangial cells were
routinely cultured at 371C in an environment of 95% air and 5%
CO2 in RPMI media (Sigma) containing 5 mmol/l glucose,
15 mmol/l 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, and
10% fetal calf serum (JRH, Melbourne, Australia). Ethics for the use
of tissue was obtained from the Human Ethics Committee of the
University of Sydney (NSW, Australia).
Effect of AGEs on MMP-3, -7 and -10 gene expression
To examine the effect of GlyAlb on expression of MMPs, mesangial
cells (P3–P4) from three different donor kidneys were plated into
six-well plates and grown to confluence in 5 mM glucose, the media
was then changed to RPMI containing either control, GlyAlb, or
GlyAlbþAG (three wells per condition) at a concentration of 0.1%.
After 48 h, the media was collected, and the cells were washed with
PBS before extraction of RNA with Tri Reagent (Sigma). In a
separate series of experiments, mesangial cells from an additional
three donors were cultured in the presence of CML-BSA (300 mg/ml)
for 48 h. For both series of experiments, media was collected for the
measurement of MMP-3, -7, and -10 by ELISA according to the
manufacturer’s instructions (R&D Systems, Minneapolis, MN,
USA). In addition, RNA was extracted from the cells for the
measurement of gene expression of MMPs by quantitative real-time
RT-PCR (see below).
Measurement of MMP-7 activity
MMP-7 activity was determined in culture media of cells incubated
with GlyAlb or CML in the presence or absence of aminoguanidine
or in rat kidney tissue using a fluorescently labeled substrate
(Anaspec, San Jose, CA, USA). Results were compared with those
obtained for a standard concentration of MMP-7 and an internal
control as supplied with the kit. By this method, the total amount of
MMP-7 in the culture media is determined after activation of the
enzyme by the addition of aminophenyl mercuric acetate (Sigma)
for 1 h before addition of the fluorescent substrate. The sample and
substrate are then incubated at room temperature for 1 h, and the
activity of MMP-7 was measured fluorimetrically at 355 nm
excitation and 450 nm emission.
Effects of TGF-b on MMP-7 expression and activity
To evaluate the effects of TGF-b on MMP-7 expression, cells were
cultured in serum-free RPMI media in the presence of 5 mM glucose
and either 5 or 10 ng/ml TGF-b1 (R&D Systems). After 48 h, the
medium was removed and the RNA extracted from the cells for
measurement of MMP-7 gene expression and the media was
collected for measurement of MMP-7 protein and activity. To
further determine the role of TGF-b on the effects of AGEs on
MMP-7 expression and activity, mesangial cells were cultured in
serum-free RPMI containing 5 mM glucose and either control or
GlyAlb (0.1%) alone or in combination with 30 mg/ml of neutraliz-
ing anti-TGF-b antibody (R&D Systems), or with 30 mg/ml of
control immunoglobulin. After 48 h, the medium was removed and
stored at 201C for the measurement of MMP-7 protein and
activity. The cells were washed in PBS and the RNA extracted for
measurement of MMP-7 expression.
Rodent studies
Diabetes was induced in Sprague–Dawley rats (n¼ 16) by the
intravenous injection of streptozocin (50 mg/kg, Calbiochem,
Darmstadt, Germany). A further 12 age-matched animals, injected
with citrate buffer, were used as non-diabetic controls. All diabetic
rats received 4 U/day long-acting insulin (Ultratard, Novo-Nordisk,
Bagsvegaard, Sweden) to maintain body weight and to prevent
ketoacidosis. To determine the effect of inhibition of glycation on
kidney changes, diabetic animals and non-diabetic control rats were
further randomized to receive the glycation inhibitor aminoguani-
dine (DþAG: n¼ 8 and NDþAG: n¼ 4) in their drinking water
(1 g/l). This was equivalent to a mean dose of (2 mg/kg/day) for the
duration of the study. Both insulin and aminoguanidine treatments
were commenced 1 week after the induction of diabetes.
At 32 weeks of duration of diabetes, rats were anesthetized with
pentobarbital and the kidneys excised. One kidney was immediately
snap-frozen and stored at –801C for later RNA extraction using
RNeasy kit (Qiagen, Melbourne, Australia) and also protein
extraction for the measurement of MMP-7 activity. The other
kidney was processed for immunohistochemistry as described
previously.34 Blood obtained at death was collected in lithium
heparin tubes, spun, separated, and stored at –201C. HbA1c was
determined by high-performance liquid chromatography. All aspects
of the experiment were approved by the Animal Ethics Committee
of the University of Melbourne (Fitzroy, Melbourne, Australia).
Human kidney tissue
The assessment of gene expression and light microscopic studies
were performed on surplus renal biopsy tissue taken for diagnostic
purposes from seven patients with type 2 diabetic nephropathy, as
described previously.39 Biopsies were divided into two portions. One
was immediately snap-frozen in liquid nitrogen and stored at 801C
for subsequent RNA extraction. A second was fixed in neutral-
buffered formalin and embedded in paraffin for later immunohis-
tochemical analysis. In all cases, the underlying histology
represented typical changes of diabetic nephropathy without
evidence of other discernible lesions as seen by light microscopy,
immunofluorescence, or electron microscopy. Control tissue was
obtained from eight patients, who underwent nephrectomy for the
treatment of tumor with tissue obtained from the normal pole. All
control patients had normal renal function, were normotensive, and
had no evidence of urinary protein (Table 2). Sections of kidney
remote to the tumor were selected and snap-frozen at 801C and
normal histology confirmed microscopically (n¼ 8) and biopsy
samples from diabetic patients (n¼ 7). The protocol for the
acquisition of human kidney tissue was approved by the Ethics
Committee of St Vincent’s Hospital (Melbourne, Australia). To
extract RNA, tissue samples were homogenized (Ultra-Turrax, Janke
and Kunkel, Staufen Germany) and the RNA was extracted using the
mini RNeasy kit (Qiagen). The RNA concentration and purity of
each sample was determined by measurement of absorption at 240
and 260 nm. An aliquot of each RNA sample was reversed
transcribed and the gene expression of MMP-7 determined by
real-time PCR as described in detail below.
Real-time RT-PCR analysis
For all cell and tissue samples, total RNA (1mg) was reverse
transcribed into cDNA using oligo dT (10 pmol, Invitrogen,
Carlsbad, CA, USA), random hexamers (10 pmol, Invitrogen), and
Superscript III (Invitrogen) according to the manufacturer’s
instructions, using specific primers for MMPs -3, -7, and -10
486 Kidney International (2007) 72, 481–488
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(Table 3). Gene expression was determined by quantitative RT-PCR
using the Platinum Plus QPCR kit (Invitrogen), SYBR green for
detection and ROX as an internal control. For all MMPs species, the
identity of the PCR products was confirmed by sequencing
(SUPAMAC, Sydney, Australia). For each of the MMP genes,
standard curves were generated from PCR products ligated into
pGEM Teasy (Promega, Madison, WI, USA) and the linear
amplification range was determined. The cycle threshold for all
unknown samples fell within the linear range. To control for
variations in initial RNA concentration and reverse transcription
efficiency, the values for all samples were corrected for the
housekeeping gene b-actin, and the results were expressed as a
ratio. Each cell and tissue sample was analyzed in duplicate in two
separate PCR reactions.
Immunohistochemical analysis
Fibronectin was assessed immunohistochemically in rodent kidney
tissue as described previously.34 Briefly, tissue obtained as described
above was fixed in 4% paraformaldehyde and embedded in paraffin.
Sections (4mm) were cut, deparaffinized, and rehydrated. To retrieve
antigenicity from formalin fixation, sections were incubated for
10 min in 10 mmol/l sodium citrate buffer using a microwave oven.
Endogenous peroxidase activity was blocked by further pretreatment
with 1% H202/methanol followed by incubation in blocking
solution. The sections were then incubated with either fibronectin
antibody (DAKO, Carpinteria CA, USA) at a concentration of 1:200.
The primary antibodies were diluted in PBS with 2% BSA, were
applied to tissue sections, and were incubated at 41C overnight in a
humidified atmosphere. The slides were then washed with PBS and
incubated with rabbit anti-mouse horseradish peroxidase-conju-
gated secondary antibody or for the fibronectin-staining rabbit anti-
goat (1:200) biotinylated immunoglobulin (DAKO) followed by
avidin–biotin peroxidase complex (Vector, Burlingame, CA, USA).
Immunoreactivity was visualized with the chromagen diaminoben-
zidine tetrachloride (0.025%, Sigma) in PBS. Staining for the
negative controls proceeded in the same manner as for the primary
antibodies. All sections were counterstained with hematoxylin.
Statistical analysis
Normally distributed data obtained from PCR analysis of gene
expression were expressed as mean7s.d. Results were compared
using analysis of variance (NCSS statistical package) with post hoc
comparisons using Duncans Multiple t-test. Significance was
accepted at the Po0.05.
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